ALK inhibitors for ALK-altered paediatric malignancies

Affiliations

¹ Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Center, Paris-Saclay University, 94805 Villejuif, France. Electronic address: laurence.brugieres@gustaveroussy.fr.
² Division of Hematology/Oncology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
³ Division of Pediatric Hematology-Oncology, Children's Hospital of the Kings Daughter, Norfolk, VA, USA.

Comment

Laurence Brugieres et al. Lancet Oncol. 2021 Dec.

. 2021 Dec;22(12):1646-1648.

doi: 10.1016/S1470-2045(21)00608-2. Epub 2021 Nov 12.

¹ Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Center, Paris-Saclay University, 94805 Villejuif, France. Electronic address: laurence.brugieres@gustaveroussy.fr.
² Division of Hematology/Oncology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
³ Division of Pediatric Hematology-Oncology, Children's Hospital of the Kings Daughter, Norfolk, VA, USA.

No abstract available

Conflict of interest statement

LB is a member of an advisory board for Takeda without personal remuneration. EL is a consultant for Pfizer. ZA declares no competing interests.

Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
Fischer M, Moreno L, Ziegler DS, Marshall LV, Zwaan CM, Irwin MS, Casanova M, Sabado C, Wulff B, Stegert M, Wang L, Hurtado FK, Branle F, Geoerger B, Schulte JH. Fischer M, et al. Lancet Oncol. 2021 Dec;22(12):1764-1776. doi: 10.1016/S1470-2045(21)00536-2. Epub 2021 Nov 12. Lancet Oncol. 2021. PMID: 34780709 Clinical Trial.